Header

Skip to main content

Slider

ATTRUBY (acoramidis) is now FDA-APPROVED for ATTR-CM in U.S.

Attruby (Acoramidis), was approved by the FDA on November 22, 2024 for ATTR-CM patients (both wild-type and hereditary) in the U.S.

Orally-administered, Attruby is a near complete TTR stabilizer (>= 90%), designed to reduce cardiovascular death and cardiovascular-related hospitalization. In addition, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A.

To honor the courage of our U.S. clinical trial participants, BridgeBio will provide these patients Attruby free for life.

Attruby

PRESS RELEASE

 

ForgingBridges:  Patient Support Services

FDA CLEARS AI SCREENING TOOL FOR CARDIAC AMYLOIDOSIS

“Echocardiography is a powerful tool for evaluating cardiac structure and function and is central to the detection and monitoring of disease,” Ross Upton, PhD, CEO and founder of Ultromics, said in a statement. “However, there are some diseases that are very challenging for even the most expert clinician to detect on an echocardiogram. Requiring only a single apical four-chamber image, EchoGo Amyloidosis identifies cardiac amyloidosis and will help drive earlier access to appropriate treatment and care for patients with this underdiagnosed disease.”

LEARN MORE ABOUT EchoGo Amyloidosis

Patient Panel Provides Medical Students Insights into Living with a Rare Disease

The Chicago College of Osteopathic Medicine (CCOM) held a patient panel about amyloidosis, a rare disease where abnormal proteins build up in different tissues and organs. The patient panel was an opportunity for medical students to increase their awareness of amyloidosis and hear a patient’s experience living with the rare disease. According to the Amyloidosis Foundation, there are less than 200,000 people in the U.S. who have been diagnosed with amyloidosis.

George Borrelli, D.O., Chair, Clinical Integration, CCOM, welcomed the audience to the patient panel and discussed the importance of the supplemental learning opportunity for the students. “It gives you an opportunity to not only learn about a disease, but to get an account from a patient who has actually gone through the situation.” Dr. Borrelli elaborated, “The earlier this disease is diagnosed, the better the outcomes are. For so many years, this disease has been an enigma, difficult to diagnose, and slipped through many clinicians’ fingers.”

Ozzie Giglio, who is living with amyloidosis, visited Midwestern University and shared his experience with the rare disease. Ozzie is a patient educator with the Amyloidosis Speakers Bureau.

Medical student Kelly Brake (CCOM ’27) said, “It was nice to hear a patient account during our coursework years. It’s a good reminder of the challenges that patients face in healthcare.” She also expressed her gratitude for CCOM’s enrichment of classroom learning with experiences like this event.

The link below is to the full article published by Midwestern University.

https://www.midwestern.edu/news-stories/patient-panel-provides-medical-students-insights-living-rare-disease

Congressional Hill Briefing, Improving Care for Veterans with Rare Diseases: Establishing a National Commission

We, with other members of the amyloidosis community, were proud to join an important meeting hosted by the Center for Patient Advocacy Leaders (CPALs). They hosted a Congressional Hill Briefing, Improving Care for Veterans with Rare Diseases: Establishing a National Commission, at the U.S. Capitol Visitor Center in Washington, DC. This briefing was designed to bring together Veterans/Veterans’ advocates, rare disease advocates, patients, and congressional staff to address unmet needs of Veterans with rare diseases and explore collective action to help ensure Veterans with rare diseases get the comprehensive, patient-centered care and treatment they need and deserve.

Mackenzie’s Mission recognized by Mayo Clinic in the Hall of Benefactors

We thank the Mayo Clinic for the recognition of our ongoing support of their Amyloidosis Research Fund. Starting in 2017, shortly after Mackenzie’s Mission was founded, our cumulative support has been meaningful, and we are now Distinguished Benefactors.

In addition, we are proud to be in the Mayo Clinic Hall of Benefactors!

Dr. Morie Gertz at the Mayo Clinic works with a multidisciplinary team of experts and helps to lead research initiatives which are widely recognized worldwide as one of the original amyloidosis centers of excellence.

While we know that funding research, bio banks, conducting clinical trials, and more requires significant funds, it is our hope that our year-to-year support helps them do more and make an even bigger difference.

We are eternally grateful to the amyloidosis team at the Mayo Clinic and all they do for our patient community to improve lives.

Mackenzie’s Mission at the Bradley Z Naifeh Amyloidosis Conference 2024!

We were proud to be part of the 2nd annual Bradley Z. Naifeh Amyloidosis Conference 2024 at Houston Methodist! On day 1 the auditorium was filled with healthcare professionals who learned about the many facets of the clinical side of amyloidosis from experts such as Dr. Ron Witteles of Stanford and Dr. Angela Dispenzieri of Mayo Clinic.

On day 2 the auditorium was packed with patients and caregivers of all types of amyloidosis, offering a wonderful opportunity to learn about the disease, resources available, and network with other patients and caregivers.

Mackenzie and Deb had the chance for a photo op with Megan Fleischfresser Naifeh (daughter of Bradley Z. Naifeh who lost his battle with AL Amyloidosis) and Dr. Arvind Bhimaraj (co-host of the conference).

We thank the Naifeh family for their support of this valuable annual conference.

ASB Participates in Rare Disease Day 2024!

The Amyloidosis Speakers Bureau was thrilled to participate on Rare Disease Day! One way we were part of the celebration was for our patient educator Sean to share his journey at Keck Graduate Institute’s Rare Disease Awareness Fair.

 

The Story Behind the Amyloidosis Speakers Bureau

The story behind the Amyloidosis Speakers Bureau (ASB) is very special. In this video we hear where the original concept of patients presenting to medical students came from — Dr. Gordon Huggins of Tufts University School of Medicine. Hear how he was “auditioning” his patients to speak to his class of second year cardiovascular medical students, and then he met Charolotte Raymond. It was an experience so meaningful it inspired Charolotte to conceptualize a program whereby patients would educate medical students across the country. She partnered with Mackenzie’s Mission in 2018, where together we took her original concept and collectively developed it into the Amyloidosis Speakers Bureau. The ASB was officially founded February 1, 2019.

Humanizing Medical Education: Beyond Bullet Points

The content of medical education is appropriately clinically centered. The delivery of this content remains relatively unchanged over the decades – typically taught by medical professionals through lectures, PowerPoint presentations, and patient case studies. We posit that there is an essential missing component: the patient voice. During the didactic years, medical students rarely hear from patients about their symptoms, diagnostic journey, emotional management, support and resources, and relationship with the medical community. By humanizing medical didactic education, patient insights can offer an impactful and durable education that complements traditional didactics, developing what we believe will be better and more empathetic future medical practitioners.

2023: Mackenzie’s Mission – Our Report Card

2023: The Year of Many Accomplishments

This was our sixth full year of operation. We were busy with lots of activities to advance our mission to make a difference in the fight against Amyloidosis and lay a strong foundation for the future. Operationally, we continued to run extremely efficient and lean, and laser-focused on making a difference in multiple ways.

  • Raising awareness about Amyloidosis, which we believe can lead to earlier diagnosis and better outcomes for patients.
  • Supporting medical research on Amyloidosis, seeking to understand more, develop better and less invasive diagnostic approaches, and develop more effective treatments, all of which will improve and extend lives.

 

RAISING AWARENESS

The first part of our mission is raising awareness. 

Amyloidosis Speakers Bureau (ASB): Back in February 2019 we launched the Amyloidosis Speakers Bureau as the cornerstone of our raising awareness effort. It is a direct outreach with live presentations by patient educators, done both virtually and in-person.

Amyloidosis is considered a rare disease and is not well known. However, there is a belief within the medical community that this disease is not rare, it is underdiagnosed or diagnosed when it is too late to make a difference. The complexity of this disease makes diagnosis one of the biggest challenges affecting patient lives. It is not uncommon to hear from patients that it took multiple years and multiple doctors to ultimately arrive at a correct diagnosis, all the while the disease continues to progress. Until a cure is found, it is imperative to raise awareness within the medical community to close this educational gap so that a diagnosis can be determined much sooner, enabling effective treatments and therapies to slow the disease progression and improve patient survival.

 

Our response to this crisis is the Amyloidosis Speakers Bureau (ASB), an initiative focused on educating the medical community about this disease through presentations from amyloidosis patients, an educational video from medical experts, and our monthly educational updates. Our target audience is the next generation of doctors during their first/second year of medical school, as well as internal medicine residency programs for physicians launching their medical career. 

 

During 2023, we gave 81 presentations to over 3,800 medical students and residents. Since we began in the fall of 2019, we have given 289 presentations to over 14,000 medical students and residents!

 

ASB Published Research: In June we published our research paper “Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients’ narratives on medical students’ knowledge, attitudes, and behavioral intent”, co-authored with one of our speakers Dr. Kathy Rowan, a passionate social scientist Dr. Adebanke Adebayo, and amyloidosis expert Dr. Vaishali Sanchorawala. The purpose was to analyze the impact of an ASB presentation on medical students and assess whether we were making a difference. Needless to say, evidence confirms the ASB DOES make a difference! You can read it here in PubMed.

 

New Educational Video Series: In September we launched a new Expert Insights Into Amyloidosis series of short educational videos from our ASB Advisors. Developed for our medical student/resident audience, we have found that our patient community is also finding value in these videos. These 10-15 minute videos have thus far proven to be a massive hit. In just over three months, the initial 16 videos have amassed over 45,000 views. Shockingly awesome! Good news is we continue to have more videos in the works. To view, visit the Education hub of our new website and click on the “Expert Insights” category.

 

Videos to Humanize Amyloidosis: The complexity of this disease makes it elusive and difficult to diagnose. It isn’t well known. We recognize the importance of increasing the clinical awareness within the medical community, yet we also believe in the importance of humanizing this disease – bringing the patient to life. In 2023 we created our 3rd FACES of Amyloidosis video, complementing versions previously done in 2018 and 2020. Wildly popular and powerful, they showcase the diversity of our amyloidosis patient community. In addition, bringing the patient voice to clinical medicine is also important, and a recent video explores this imperative (Humanizing Medical Education).

 

Call to Action Video Directed at Medical Educators: In November we relaunched our important call-to-action video “Closing the Medical Education Gap: The urgency to act is NOW”, developed for the medical educator audience. Watch here (7:50 mins). Over a thousand views so far.

 

New Website: In November we launched our new website, providing more information about what we’re doing, links to resources for the patient community, as well as a new digital platform for education to both the medical trainees and patient community.

 

Continuing Medical Student Education: After every presentation we invite medical students interested in continuing to learn about amyloidosis to join our ASB Briefs mailing list. Today, that list numbers over 825! Each month we send a brief discussion about some aspect of the disease with a growing library of links to informative presentations / videos by medical experts, and announcements regarding advancements in treatment. The intention is to keep amyloidosis more front-of-mind and educate on the many facets of this complex and multi-systemic disease.

 

Digital Voice: We appreciate that thanks to social media platforms, our voice of education and support can far extend beyond our direct outreach. We invite you to follow us on Facebook (Mackenzies Mission), LinkedIn (Mackenzies Mission), and Twitter “X” (@Amyloidosis_ASB) for frequent posts about what’s going on.

 

SUPPORTING MEDICAL RESEARCH

The second part of our mission is to help advance research. Research is at the core of developing new therapies to improve patient lives. Patients benefit from research through early access to novel therapies, new tests for earlier/easier diagnosis, and new approved treatments. However, research is expensive, takes many years, and is absolutely critical to the deepening of knowledge fueling these advancements. And while significant progress continues to be made, much more needs to be done.

No progress in the fight against this disease happens without funding, and the NIH provides a mere fraction of what is needed. Researchers require money to run their labs, maintain bio banks, purchase equipment, run clinical trials, and more. To operate, they rely on private foundations (like Mackenzie’s Mission), grants, and individual donors.

Each year, a portion of our budget goes towards advancing research. We are grateful for the support received from donors like you and fundraisers, and proud that collectively these funds are changing the therapeutic landscape and benefiting patients.

In 2023, our donations pushed us over the $1,000,000 threshold for total money donated!

 

WHAT ARE OUR GOALS FOR 2024?

In short, keep doing what we are doing, but do more of it.

 

Raising Awareness

  • Remain focused on the Amyloidosis Speakers Bureau (ASB). With 289 presentations to more than 14,000 medical students and residents, this is where we believe we can make the biggest impact from our efforts. Engagement from the amyloidosis patient community to serve as patient educators, securing meaningful grants, and proceeds from donations/fundraisers will be key to complement the operational and legal infrastructure required.
  • Opportunistically speak at conferences or sessions that are aligned with our mission. For example, we will be speaking at the Bradley Z. Naifeh Amyloidosis Conference in March, the Cardiovascular Institute of Philadelphia in April/May, and the International Symposium on Amyloidosis (ISA) in May.
  • Develop a digital outreach program to expand beyond our direct outreach on our social media platforms, with the goal of increasing the following of our educational content among the patient community and in particular, the medical community.
  • Add new and diverse content about this disease to our website education hub and patient resources.
  • Maintain our monthly medical student and MD/Resident mailings, as well as our broad Mackenzie’s Mission newsletter.
  • Explore additional opportunities, both large and small, which enable us to further spread the word on the importance of early diagnosis.

 

Supporting Medical Research

  • Continue our support to advance medical research by donating a meaningful portion of our budget (excluding ASB grants and directed donations) to leading research institutions whom we know are working to advance their knowledge, support patients, run clinical trials to provide early access to developing drugs, and find new therapies to fight this disease.

 

WITH MUCH APPRECIATION AND GRATITUDE

This last year you may have donated cash or securities, sponsored a Facebook fundraiser, played in our Play FORE the Cure charity golf tournament, participated in our 3rd FACES of Amyloidosis video, or given us a grant to support our Amyloidosis Speakers Bureau medical education initiative. You may have been an Amyloidosis Speakers Bureau patient educator, liked/shared our Facebook posts, or taken the time to read our posts or newsletter to learn about amyloidosis. Whether you did one of these or many, you helped us push forward our fight against this disease and we appreciate your support.

 

We also want to extend a special thank you to our volunteers who passionately and graciously devote their time and expertise. Whether to help at our charity golf tournament, or one of many facets of the Amyloidosis Speakers Bureau (e.g., speaker development, running Zoom presentations, researching contacts, writing ASB Briefs, writing our ASB research paper to prepare for publication, or producing our videos), we can’t even begin to accomplish all that we have without YOU. Thank you!

 

I am encouraged by the impact Mackenzie’s Mission is already making after just a few short years. Connecting with the amyloidosis community and working together to make an impact is extremely rewarding. There is much work to be done, but with so much help from the community and our supporters I know we can win this fight!

 

With warm regards for a wonderful and hopeful 2024,

 

Mackenzie

 

AN UPDATE ON ME

This past year was a busy one! Mackenzie’s Mission and the Amyloidosis Speakers Bureau accomplished many important projects, laying the foundation for an exciting future. Outside of the foundation, I completed my didactic year in the Physician Assistant Program at Northeastern University and am now well into my second and last year, consisting of clinical rotations. I graduate in August 2024 and will look to start my career; in what specialty, I’m not sure yet! Between graduation and starting my career I will be traveling across India and Nepal. As for my disease, I am monitored closely, and it continues to be under control. I feel great!

This website uses cookies

This site uses cookies to provide more personalized content, social media features, and ads, and to analyze our traffic. We might share information about your use of our site with our social media, advertising, and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will never sell your information or share it with unaffiliated entities.

Newsletter Icon